FTC loses Impax pay-for-delay case

A Federal Trade Commission administrative law judge has found that the procompetitive benefits of a reverse-payment settlement between drugmakers Endo and Impax outweighed the anticompetitive harm.

Get unlimited access to all Global Competition Review content